Loading...
XSHE
002644
Market cap538mUSD
Jul 10, Last price  
7.21CNY
1D
0.84%
1Q
-16.84%
Jan 2017
-36.19%
IPO
121.85%
Name

Lanzhou Foci Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002644 chart
P/E
74.82
P/S
4.02
EPS
0.10
Div Yield, %
0.17%
Shrs. gr., 5y
0.01%
Rev. gr., 5y
2.29%
Revenues
916m
-6.60%
219,012,177232,209,322262,406,038271,184,334266,362,195291,528,279399,071,335327,584,499363,255,419501,139,716544,581,045628,815,164668,051,013817,640,826817,640,8251,019,176,3391,042,388,8321,163,134,313980,225,387915,533,598
Net income
49m
-18.08%
21,609,21436,146,83351,241,69232,060,66230,356,21030,596,43234,652,86842,947,62460,926,24074,092,78974,278,60674,852,565108,017,97093,258,95693,258,962108,654,174108,654,18267,189,70960,069,81949,207,166
CFO
184m
+371.85%
105,608,341602,5633,464,82956,179,2632,426,0310093,746,66464,114,41656,901,04466,423,06236,663,11247,822,98562,888,16211,854,64272,369,95665,714,29938,984,923183,949,347
Dividend
Jun 24, 20250.012 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

LanZhou Foci Pharmaceutical Co.,Ltd. is a prominent pharmaceutical entity based in China, primarily focused on the manufacturing and distribution of traditional Chinese medicines. Its diverse product line, offered under the "Min Shan" and "Foci" brand names, encompasses a variety of formats, including pills, tablets, capsules, and granules. Beyond its production activities, the company actively pursues research and development initiatives aimed at pioneering novel herbal remedies. Its global footprint extends to approximately 27 countries, with key export markets including the United States, Canada, Japan, Australia, Russia, Ukraine, Singapore, Indonesia, Thailand, Malaysia, New Zealand, and Hong Kong. Established in 1929, the firm's headquarters are located in Lanzhou, China. LanZhou Foci Pharmaceutical Co.,Ltd. operates as a subsidiary of the Lanzhou Foci Pharmaceutical Factory.
IPO date
Dec 22, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT